Compare GENC & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GENC | CRBU |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.2M | 203.9M |
| IPO Year | 1995 | 2021 |
| Metric | GENC | CRBU |
|---|---|---|
| Price | $14.50 | $1.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $16.00 | $10.75 |
| AVG Volume (30 Days) | 25.3K | ★ 1.2M |
| Earning Date | 02-06-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.08 | 3.64 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $48,943,000.00 | N/A |
| Revenue This Year | $6.36 | N/A |
| Revenue Next Year | $8.32 | $10.48 |
| P/E Ratio | $61.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.80 | $0.66 |
| 52 Week High | $17.40 | $3.53 |
| Indicator | GENC | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 45.39 | 54.84 |
| Support Level | $13.56 | $1.70 |
| Resistance Level | $14.68 | $2.07 |
| Average True Range (ATR) | 0.54 | 0.11 |
| MACD | -0.19 | -0.01 |
| Stochastic Oscillator | 28.89 | 64.63 |
Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.